The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Danny Vesprini; Steven A. Narod; John Trachtenberg; Juanita Crook; Farid Jalali; John Preiner; Srikala Sridhar; Robert G. Bristow

doi:10.5489/cuaj.10080

The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Danny Vesprini, Steven A. Narod, John Trachtenberg, Juanita Crook, Farid Jalali, John Preiner, Srikala Sridhar, Robert G. Bristow

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therapeutic ratio (ratio of tumour response to normal tissue toxicity). We describe 3 patients treated with precision radiotherapy or cisplatin who responded favourably to both agents, yet did not suffer undue toxicity. We review the concept of treating such patients with agents that are selectively toxic to repair-deficient tumours.

Original language	English
Pages (from-to)	E31-E35
Number of pages	5
Journal	Journal of the Canadian Urological Association
Volume	5
Issue number	2
DOIs	https://doi.org/10.5489/cuaj.10080
Publication status	Published - Apr 2011

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5489/cuaj.10080

Cite this

@article{3d25843a4c684248902bd448cae6ba9f,

title = "The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers",

abstract = "Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therapeutic ratio (ratio of tumour response to normal tissue toxicity). We describe 3 patients treated with precision radiotherapy or cisplatin who responded favourably to both agents, yet did not suffer undue toxicity. We review the concept of treating such patients with agents that are selectively toxic to repair-deficient tumours.",

author = "Danny Vesprini and Narod, \{Steven A.\} and John Trachtenberg and Juanita Crook and Farid Jalali and John Preiner and Srikala Sridhar and Bristow, \{Robert G.\}",

year = "2011",

month = apr,

doi = "10.5489/cuaj.10080",

language = "English",

volume = "5",

pages = "E31--E35",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Urological Association",

number = "2",

}

TY - JOUR

T1 - The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

AU - Vesprini, Danny

AU - Narod, Steven A.

AU - Trachtenberg, John

AU - Crook, Juanita

AU - Jalali, Farid

AU - Preiner, John

AU - Sridhar, Srikala

AU - Bristow, Robert G.

PY - 2011/4

Y1 - 2011/4

N2 - Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therapeutic ratio (ratio of tumour response to normal tissue toxicity). We describe 3 patients treated with precision radiotherapy or cisplatin who responded favourably to both agents, yet did not suffer undue toxicity. We review the concept of treating such patients with agents that are selectively toxic to repair-deficient tumours.

AB - Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therapeutic ratio (ratio of tumour response to normal tissue toxicity). We describe 3 patients treated with precision radiotherapy or cisplatin who responded favourably to both agents, yet did not suffer undue toxicity. We review the concept of treating such patients with agents that are selectively toxic to repair-deficient tumours.

UR - https://www.scopus.com/pages/publications/79953283583

U2 - 10.5489/cuaj.10080

DO - 10.5489/cuaj.10080

M3 - Article

AN - SCOPUS:79953283583

SN - 1911-6470

VL - 5

SP - E31-E35

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 2

ER -

The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this